# Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)

> **NCT01844778** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 60 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Tobramycin Inhalation Powder
- **DRUG:** Tobramycin inhalation solution
- **DRUG:** Colistimethate

## Key facts

- **NCT ID:** NCT01844778
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2016-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01844778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01844778, "Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01844778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*